|
1
|
Grimm MO, Wolff I, Zastrow S, Fröhner M
and Wirth M: Advances in renal cell carcinoma treatment. Ther Adv
Urol. 2:11–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De P, Otterstatter MC, Semenciw R, Ellison
LF, Marrett LD and Dryer D: Trends in incidence, mortality, and
survival for kidney cancer in Canada, 1986–2007. Cancer Causes
Control. 25:1271–1281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Michaelson MD, Redman BG, Hudes
GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE,
et al: Activity of SU11248, a multitargeted inhibitor of vascular
endothelial growth factor receptor and platelet-derived growth
factor receptor, in patients with metastatic renal cell carcinoma.
J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dhir R, Ni Z, Lou W, DeMiguel F, Grandis
JR and Gao AC: Stat3 activation in prostatic carcinomas. Prostate.
51:241–246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang M, Page C, Reynolds RK and Lin J:
Constitutive activation of stat 3 oncogene product in human ovarian
carcinoma cells. Gynecol Oncol. 79:67–73. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Proietti CJ, Rosemblit C, Beguelin W,
Rivas MA, Díaz Flaqué MC, Charreau EH, Schillaci R and Elizalde PV:
Activation of Stat3 by heregulin/ErbB-2 through the co-option of
progesterone receptor signaling drives breast cancer growth. Mol
Cell Biol. 29:1249–1265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo C, Yang G, Khun K, Kong X, Levy D, Lee
P and Melamed J: Activation of Stat3 in renal tumors. Am J Transl
Res. 1:283–290. 2009.PubMed/NCBI
|
|
9
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johnston PA and Grandis JR: STAT3
signaling: Anticancer strategies and challenges. Mol Interv.
11:18–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carpenter RL and Lo HW: STAT3 target genes
relevant to human cancers. Cancers. 6:897–925. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Portt L, Norman G, Clapp C, Greenwood M
and Greenwood MT: Anti-apoptosis and cell survival: A review.
Biochim Biophys Acta. 1813:238–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Riedl SJ and Salvesen GS: The apoptosome:
Signalling platform of cell death. Nat Rev Mol Cell Biol.
8:405–413. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sinha K, Das J, Pal PB and Sil PC:
Oxidative stress: The mitochondria-dependent and
mitochondria-independent pathways of apoptosis. Arch Toxicol.
87:1157–1180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cerna D, Li H, Flaherty S, Takebe N,
Coleman CN and Yoo SS: Inhibition of nicotinamide
phosphoribosyltransferase (NAMPT) activity by small molecule
GMX1778 regulates reactive oxygen species (ROS)-mediated
cytotoxicity in a p53- and nicotinic acid
phosphoribosyltransferase1 (NAPRT1)-dependent manner. J Biol Chem.
287:22408–22417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kampa M, Nifli AP, Notas G and Castanas E:
Polyphenols and cancer cell growth. Rev Physiol Biochem Pharmacol.
159:79–113. 2007.PubMed/NCBI
|
|
19
|
Aida K, Tawata M, Shindo H, Onaya T,
Sasaki H, Yamaguchi T, Chin M and Mitsuhashi H: Isoliquiritigenin:
A new aldose reductase inhibitor from Glycyrrhizae Radix. Planta
Med. 56:254–258. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Choi YH, Bae JK, Chae HS, Choi YO, Nhoek
P, Choi JS and Chin YW: Isoliquiritigenin ameliorates dextran
sulfate sodium-induced colitis through the inhibition of MAPK
pathway. Int Immunopharmacol. 31:223–232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gaur R, Yadav KS, Verma RK, Yadav NP and
Bhakuni RS: In vivo anti-diabetic activity of derivatives of
isoliquiritigenin and liquiritigenin. Phytomedicine. 21:415–422.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jung SK, Lee MH, Lim DY, Kim JE, Singh P,
Lee SY, Jeong CH, Lim TG, Chen H, Chi YI, et al: Isoliquiritigenin
induces apoptosis and inhibits xenograft tumor growth of human lung
cancer cells by targeting both wild type and L858R/T790M mutant
EGFR. J Biol Chem. 289:35839–35848. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Auyeung KK and Ko JK: Novel herbal
flavonoids promote apoptosis but differentially induce cell cycle
arrest in human colon cancer cell. Invest New Drugs. 28:1–13. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jung JI, Chung E, Seon MR, Shin HK, Kim
EJ, Lim SS, Chung WY, Park KK and Park JH: Isoliquiritigenin (ISL)
inhibits ErbB3 signaling in prostate cancer cells. Biofactors.
28:159–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lai PH, Li KT, Hsu SS, Hsiao CC, Yip CW,
Ding S, Yeh LR and Pan HB: Pyogenic brain abscess: Findings from in
vivo 1.5-T and 11.7-T in vitro proton MR spectroscopy. AJNR Am J
Neuroradiol. 26:279–288. 2005.PubMed/NCBI
|
|
26
|
Li Y, Zhao H, Wang Y, Zheng H, Yu W, Chai
H, Zhang J, Falck JR, Guo AM, Yue J, et al: Isoliquiritigenin
induces growth inhibition and apoptosis through downregulating
arachidonic acid metabolic network and the deactivation of PI3K/Akt
in human breast cancer. Toxicol Appl Pharmacol. 272:37–48. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park I, Park KK, Park JH and Chung WY:
Isoliquiritigenin induces G2 and M phase arrest by inducing DNA
damage and by inhibiting the metaphase/anaphase transition. Cancer
Lett. 277:174–181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Wang N, Han S, Wang D, Mo S, Yu L,
Huang H, Tsui K, Shen J and Chen J: Dietary compound
isoliquiritigenin inhibits breast cancer neoangiogenesis via
VEGF/VEGFR-2 signaling pathway. PLoS One. 8:e685662013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamazaki S, Morita T, Endo H, Hamamoto T,
Baba M, Joichi Y, Kaneko S, Okada Y, Okuyama T, Nishino H, et al:
Isoliquiritigenin suppresses pulmonary metastasis of mouse renal
cell carcinoma. Cancer Lett. 183:23–30. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chae IG, Kim DH, Kundu J, Jeong CH, Kundu
JK and Chun KS: Generation of ROS by CAY10598 leads to inactivation
of STAT3 signaling and induction of apoptosis in human colon cancer
HCT116 cells. Free Radic Res. 48:1311–1321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim DH, Park KW, Chae IG, Kundu J, Kim EH,
Kundu JK and Chun KS: Carnosic acid inhibits STAT3 signaling and
induces apoptosis through generation of ROS in human colon cancer
HCT116 cells. Mol Carcinog. 55:1096–1110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Indran IR, Tufo G, Pervaiz S and Brenner
C: Recent advances in apoptosis, mitochondria and drug resistance
in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Simon HU, Haj-Yehia A and Levi-Schaffer F:
Role of reactive oxygen species (ROS) in apoptosis induction.
Apoptosis. 5:415–418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bromberg J: Stat proteins and oncogenesis.
J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aznar S, Valerón PF, del Rincon SV, Pérez
LF, Perona R and Lacal JC: Simultaneous tyrosine and serine
phosphorylation of STAT3 transcription factor is involved in Rho A
GTPase oncogenic transformation. Mol Biol Cell. 12:3282–3294. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bishayee A and Sethi G: Bioactive natural
products in cancer prevention and therapy: Progress and promise.
Semin Cancer Biol 40–41. 1–3. 2016. View Article : Google Scholar
|
|
37
|
Arumuggam N, Bhowmick NA and Rupasinghe
HP: A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO
Expression in Cancer. Phytother Res. 29:805–817. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lue HW, Cole B, Rao SA, Podolak J, Van
Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, et al: Src
and STAT3 inhibitors synergize to promote tumor inhibition in renal
cell carcinoma. Oncotarget. 6:44675–44687. 2015.PubMed/NCBI
|
|
39
|
Um HJ, Min KJ, Kim DE and Kwon TK:
Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of
human renal carcinoma Caki cells. Biochem Biophys Res Commun.
427:24–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chin YW, Jung HA, Liu Y, Su BN, Castoro
JA, Keller WJ, Pereira MA and Kinghorn AD: Anti-oxidant
constituents of the roots and stolons of licorice (Glycyrrhiza
glabra). J Agric Food Chem. 55:4691–4697. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kakegawa H, Matsumoto H and Satoh T:
Inhibitory effects of some natural products on the activation of
hyaluronidase and their anti-allergic actions. Chem Pharm Bull.
40:1439–1442. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kang SW, Choi JS, Choi YJ, Bae JY, Li J,
Kim DS, Kim JL, Shin SY, Lee YJ and Kwun IS: Licorice
isoliquiritigenin dampens angiogenic activity via inhibition of
MAPK-responsive signaling pathways leading to induction of matrix
metalloproteinases. J Nutr Biochem. 21:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kape R, Parniske M, Brandt S and Werner D:
Isoliquiritigenin, a strong nod gene- and glyceollin
resistance-inducing flavonoid from soybean root exudate. Appl
Environ Microbiol. 58:1705–1710. 1992.PubMed/NCBI
|
|
44
|
Deponte M: Glutathione catalysis and the
reaction mechanisms of glutathione-dependent enzymes. Biochim
Biophys Acta. 1830:3217–3266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Heidelberger S, Zinzalla G, Antonow D,
Essex S, Basu BP, Palmer J, Husby J, Jackson PJ, Rahman KM,
Wilderspin AF, et al: Investigation of the protein alkylation sites
of the STAT3:STAT3 inhibitor Stattic by mass spectrometry. Bioorg
Med Chem Lett. 23:4719–4722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li L, Cheung SH, Evans EL and Shaw PE:
Modulation of gene expression and tumor cell growth by redox
modification of STAT3. Cancer Res. 70:8222–8232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Park KW, Kundu J, Chae IG, Kim DH, Yu MH,
Kundu JK and Chun KS: Carnosol induces apoptosis through generation
of ROS and inactivation of STAT3 signaling in human colon cancer
HCT116 cells. Int J Oncol. 44:1309–1315. 2014.PubMed/NCBI
|
|
49
|
Sinha P and Ostrand-Rosenberg S:
Myeloid-derived suppressor cell function is reduced by Withaferin
A, a potent and abundant component of Withania somnifera root
extract. Cancer Immunol Immunother. 62:1663–1673. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sullivan LB and Chandel NS: Mitochondrial
reactive oxygen species and cancer. Cancer Metab. 2:172014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Pan MH, Sin YH, Lai CS, Wang YJ, Lin JK,
Wang M and Ho CT: Induction of apoptosis by
1-(2-hydroxy-5-methylphenyl)-3-phenyl-1,3-propanedione through
reactive oxygen species production, GADD153 expression, and
caspases activation in human epidermoid carcinoma cells. J Agric
Food Chem. 53:9039–9049. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li D, Ueta E, Kimura T, Yamamoto T and
Osaki T: Reactive oxygen species (ROS) control the expression of
Bcl-2 family proteins by regulating their phosphorylation and
ubiquitination. Cancer Sci. 95:644–650. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Schumacker PT: Reactive oxygen species in
cancer cells: Live by the sword, die by the sword. Cancer Cell.
10:175–176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jiang YQ, Zhou ZX and Ji YL: Suppression
of EGFR-STAT3 signaling inhibits tumorigenesis in a lung cancer
cell line. Int J Clin Exp Med. 7:2096–2099. 2014.PubMed/NCBI
|
